433 Vinblastine (VLB) in differentiated thyroid carcinoma (DTC) effect monitored by DNA measurements

• Published in: European journal of cancer (1990) 1995-11, Vol.31, p.S93-S93
• Main Authors: Auersperg, M., Us-Krašovec, M., Pogacnik, A., Hocevar, M., Palcic, B., Garner, D.
• Format: Article
• Language: English
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/0959-8049(95)95686-Z

Vinblastine (VLB) infusions 2 rng over 12–24 h were applied to 28 patients (21 females, 7 males, aged 32–85 years) with inoperable or metastatic DTC (follicular 13, papillary 8, Hürthle cell 7). Cytopunctures were performed before and sequentially after VLB infusions. Specimens were processed for Flow Cytometry (FCM) DNA studies (DAPI staining, PAS II cytometer) in all patients and for image cytometry analysis (Cyto-Savant™ cell image analyzer) in 12 patients. In 17/27 patients (67%) a partial response was achieved. In responders, FCM DNA measurements, changes in DNA distribution pattern (increase in S, G 2 + M compartment, polyploidy, broad G 1 peaks and debris) were observed. Cytomorphological changes after VLB appeared later than changes in DNA histograms. Image cytometry data have also been analyzed in terms ofDNA distribution diagrams, as well as changes in other nuclear Ctexture) features. Our results show that VLB is effective in DTC, and that sequential DNA measurements can predict clinical effectiveness of VLB.